Abnormal Gait, Balance, Pain, Stiffness
Conditions
Keywords
Motion platform at appropriate settings., Relief of pain., Improvement in quality of life, cognition, and mood., Effects of WBPA on cognition, mood, behavior, and functioning., Dose response effect ., Gather data for long-term (2 year) study
Brief summary
The purpose of this study is to test the effectiveness of whole body periodic acceleration for helping with symptoms of aches and pains suffered by many patients.
Detailed description
This is an unblinded cross-over study of whole-body periodic acceleration (WBPA) to ascertain if this treatment modality provides symptomatic relief of pain, stiffness, and abnormal gait and balance in a variety of conditions. The study will compare a specific mechanism of motion, whole-body periodic acceleration (WBPA), that has been shown to increase the release of beneficial mediators from the vascular endothelium into the circulation, to a control condition of slow passive motion that promotes relaxation but does not increase release of beneficial mediators into the circulation. The study tests the efficacy and safety of a commercially available device that consists of a motion platform, called Exer-Rest©, that is capable of producing both types of motion to be tested. In this investigation, 15 subjects will be randomly assigned to either procedure for 10 treatments for 2 weeks followed by a one-week wash-out period. Then the opposite treatment will be employed for two weeks.
Interventions
DEVICEWhole body periodic acceleration (Exer-Rest)
Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
Sponsors
Center for Translational Medicine
Study design
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Subjects qualifying for this study satisfy the following criteria: 1. Over 18 years of age; 2. Complain of either chronic pain, joint stiffness, and/or dysfunctions of gait and balance; 3. Complaints have been annotated by a competent physician, and the subject has been evaluated for conditions that commonly contribute to the respective symptoms; 4. Capable of completing the appropriate testing and baseline assessments, such as quantitative electroencephalography (qEEG) and questionnaires; 5. Tolerate the motion and duration of treatment of the WBPA. 6. Be available for regular visits to the research site for the duration of the study.
Exclusion criteria
WBPA is contraindicated for subjects who are pregnant or who suffer with unexplained leg pain, skin eruptions, or who have unstable spinal injuries or conditions. Subjects who cannot tolerate the motion and duration of treatment are also excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Self-report of pain | 2 weeks | Self-report of pain at start and completion of first course of treatment lasting for 2 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life | 2 weeks | Self-report of change in quality following 2 weeks of treatment. |
Countries
United States
Outcome results
None listed